๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells

โœ Scribed by Reyer T. Ottow; Alexander M. M. Eggermont; E. Philip Steller; Paul H. Sugarbaker

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
907 KB
Volume
60
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the study reported here, a model of intraperitoneal tumor in the mouse was established and shows the effectiveness of lymphokine activated killer (LAK) cells and exogenous interleukin-2 (IL-2) in the control of intraperitoneal tumor. A standard regimen was used to treat seven different tumors in three different mouse strains. In all seven cases a significant reduction in the intraperitoneal tumor mass was observed when LAK cells plus IL-2 were used as immunotherapy. A prolonged survival was also demonstrated in mice with intraperitoneal tumor. The relevance of these observations to patients with cancer was demonstrated in that allogeneic and syngeneic LAK cells were equally effective, LAK cells generated from normal and from tumor-bearing donors showed equal reactivity, and this treatment was successful in the immunocompromised host. Both IL-2 derived from an IL-2-producing subline of the EL-4 thymoma and recombinant IL-2 were equally effective in the control of intraperitoneal tumor. The local-regional effects of the intraperitoneal administration of 1L-2 were demonstrated by high levels of LAK cell cytotoxicity in peritoneal exudate cells. Intraperitoneal IL-2 or IL-2 plus LAK cell regimens should be investigated in the treatment of malignancy that spreads by implantation onto peritoneal surfaces.

๐Ÿ“œ SIMILAR VOLUMES

Adoptive immunotherapy for recurrent gli
Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2
โœ Randall E. Merchant; Angus J. Grant; Lynn H. Merchant; Harold F. Young ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 565 KB

Thirteen patients with recurrent glioblastoma were treated with adoptively transferred autologous lymphokine activated killer (LAK) cells and recombinant interleukin-2 (rIL-2). Patients' blood mononuclear cells (MNC) obtained by leukapheresis were cultured at 2.5 million MNC per ml for 3 to 5 days i

Phase iii randomized trial of interleuki
Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
โœ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

Enhanced local dendritic cell activity a
Enhanced local dendritic cell activity and tumor-specific immunoresponse in combined radiofrequency ablation and interleukin-2 for the treatment of human head and neck cancer in a murine orthotopic model
โœ Koichiro Saito; Koji Araki; Nishant Reddy; Wei Guang; Bert W. O'Malley Jr; Daqin ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 443 KB

## Abstract ## Background. Radiofrequency ablation (RFA) is a minimally invasive tumor destruction technique and can provide the antigen source initiating tumor immunity. However, induced immune response is weak and requires additional immunotherapy for optimized RFA treatment against cancer. ##